Qizheng Tibetan Medicine Selected as Part of the First Batch of China’s OTC Brand Cluster

Release time:

2021-10-21 17:31

From October 18 to 21, 2021, the first China OTC Conference and the China Traditional Chinese Medicine Promotion Conference—Healthy China 2021—were held in Guangzhou, marking the official launch of the China OTC Brand Cluster. Qizheng Tibetan Medicine was selected as one of the first members of the China OTC Brand Cluster, thanks to its strong industry influence and excellent reputation. Liu Kailie, President of Qizheng Tibetan Medicine, was honored with the title of “Honored Figure of the First China OTC Conference.” It is reported that only 18 companies were initially included in the China OTC Brand Cluster, among them well-known industry giants such as Beijing Tongrentang, Baiyunshan, and China Resources Sanjiu.

Millennial Tibetan medicine, modernly carried forward. For 26 years, Qizheng Tibetan Medicine has been dedicated to the research, development, production, and sales of Tibetan medicines, bringing these traditional remedies out of the plateau region, securing a prominent position in China’s pharmaceutical market, and expanding overseas to benefit hundreds of millions of patients. As a result, the company has become a leading enterprise in the modern Tibetan medicine industry. Since its IPO 12 years ago, the company has continuously pushed beyond its limits, achieving steady growth, expanding its market share, and sustaining robust increases in net profit. Upholding the principle of sustainable development and fulfilling its corporate social responsibility, the company has established a sustainable operational framework tailored to its own development needs and built a business ecosystem aligned with long-term interests. It has received numerous prestigious awards, including the “Global Compact China Best Practice Case,” the “CSR CHINA Model Award,” and the “Best CSR Strategy Award.” In 2020, Ms. Lei Jufang, Chairperson of the company, was named one of the “2020 UN Sustainable Development Goals Chinese Pioneers.”

The Chinese OTC Brand Cluster was commissioned by the China Brand Building Promotion Association and jointly established by the China Over-the-Counter Drug Association, the China Traditional Chinese Medicine Association, the China Chemical Pharmaceutical Industry Association, and the China Pharmaceutical Quality Management Association. It is primarily dedicated to the cultivation, evaluation, promotion, and protection of cluster brands, aiming to build a group of internationally renowned Chinese OTC brands that embody corporate strength, lead the industry, represent the nation’s image, and can successfully go global and gain widespread recognition.

During the conference, the “2021 China Over-the-Counter Drug Product Comprehensive Statistical Ranking” was released, with Qizheng Tibetan Medicine ranking 38th. The “2021 China Top OTC Drug Products List” was also announced, and Qizheng® Xiaotong Paste once again received a prestigious award. Qizheng® Xiaotong Paste is a classic Tibetan medicine formula—a nationally classified confidential product—that has been a bestseller for over 20 years. It demonstrates remarkable efficacy in relieving both acute and chronic musculoskeletal pain, characterized by potent medicinal effects, rapid pain relief, and long-lasting therapeutic benefits, earning high praise from patients.

Promote wisdom and care for health. In the future, Qizheng Tibetan Medicine will continue to remain patient-centered and clinically driven, staying true to our original aspiration and striving forward with dedication to bring patients even greater clinical benefits.

Reporting media: Approximately surveyed

Report link: https://www.yuediaoyan.com/research/index.php/Home/Ygkx/ygkx_detail/id/17097

Qizheng Tibetan Medicine Honored as a “2021 National Demonstration Enterprise for Technological Innovation”

Qizheng Tibetan Medicine has been named industry champion and ranked among the Top 10 brands with the fastest value growth on the “Hurun Billion-Dollar Potential Brand List.”